TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Gross Margin
- Gross margin · 12 months: Value 52.46%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 52.46% | Gross profit / revenue. Period ending 2026-06-30. $9.08B ÷ $17.32B × 100 ≈ 52.46% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 9.08B USD | Gross Profit |
| Revenue | 17.32B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 8.23B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $9.08B | $17.32B | $8.23B | 52.46% |
| 2026-03-31 | $9.03B | $17.35B | $8.32B | 52.07% |
| 2025-12-31 | $8.94B | $17.26B | $8.32B | 51.79% |
| 2025-09-30 | $8.40B | $16.78B | $8.37B | 50.09% |
| 2025-06-30 | $8.25B | $16.63B | $8.38B | 49.60% |
| 2025-03-31 | $8.17B | $16.62B | $8.45B | 49.17% |
| 2024-12-31 | $8.06B | $16.54B | $8.48B | 48.74% |
| 2024-09-30 | $8.36B | $16.77B | $8.41B | 49.83% |
| 2024-06-30 | $8.06B | $16.29B | $8.23B | 49.49% |
| 2024-03-31 | $7.83B | $16.00B | $8.17B | 48.95% |
| 2023-12-31 | $7.64B | $15.85B | $8.20B | 48.25% |
| 2023-09-30 | $7.00B | $15.27B | $8.27B | 45.83% |
| 2023-06-30 | $6.82B | $15.02B | $8.20B | 45.40% |
| 2023-03-31 | $6.82B | $14.93B | $8.11B | 45.66% |
| 2022-12-31 | $6.97B | $14.93B | $7.95B | 46.72% |
| 2022-09-30 | $7.25B | $15.14B | $7.89B | 47.90% |
| 2022-06-30 | $7.38B | $15.43B | $8.06B | 47.81% |
| 2022-03-31 | $7.46B | $15.56B | $8.10B | 47.93% |
| 2021-12-31 | $7.59B | $15.88B | $8.28B | 47.83% |
| 2021-09-30 | $7.59B | $16.23B | $8.64B | 46.77% |
| 2021-06-30 | $7.65B | $16.32B | $8.67B | 46.86% |
| 2021-03-31 | $7.54B | $16.28B | $8.74B | 46.31% |
| 2020-12-31 | $7.73B | $16.66B | $8.93B | 46.38% |
| 2020-09-30 | $7.64B | $16.67B | $9.04B | 45.80% |
| 2020-06-30 | $7.61B | $16.79B | $9.18B | 45.35% |
| 2020-03-31 | $7.74B | $17.09B | $9.35B | 45.30% |
| 2019-12-31 | $7.54B | $16.89B | $9.35B | 44.63% |
| 2019-09-30 | $7.55B | $17.45B | $9.91B | 43.25% |
| 2019-06-30 | $7.70B | $17.72B | $10.02B | 43.44% |
| 2019-03-31 | $7.84B | $18.08B | $10.25B | 43.34% |
| 2018-12-31 | $8.30B | $18.85B | $10.56B | 44.00% |
| 2018-09-30 | $8.91B | $19.69B | $10.78B | 45.25% |
| 2018-06-30 | $9.54B | (m) | $11.24B | (m) |
| 2018-03-31 | $10.33B | $21.80B | $11.47B | 47.40% |
| 2017-12-31 | $10.82B | $22.39B | $11.56B | 48.36% |
| 2017-09-30 | $11.67B | $23.42B | $11.74B | 49.85% |
| 2017-06-30 | $11.83B | $23.37B | $11.54B | 50.62% |
| 2017-03-31 | $11.89B | $22.72B | $10.84B | 52.31% |
| 2016-12-31 | $11.86B | $21.90B | $10.04B | 54.14% |
| 2016-09-30 | $11.32B | $20.29B | $8.98B | 55.77% |
| 2016-06-30 | $11.29B | $19.55B | $8.27B | 57.72% |
| 2016-03-31 | $11.31B | $19.48B | $8.17B | 58.06% |
| 2015-12-31 | $11.36B | $19.65B | $8.30B | 57.79% |
| 2015-09-30 | $11.40B | $19.94B | $8.54B | 57.16% |
| 2015-06-30 | $11.44B | $20.17B | $8.74B | 56.69% |
| 2015-03-31 | $11.20B | $20.25B | $9.06B | 55.28% |
| 2014-12-31 | $11.06B | $20.27B | $9.22B | 54.54% |
| 2014-09-30 | $11.06B | $20.53B | $9.47B | 53.87% |
| 2014-06-30 | $10.88B | $20.54B | $9.65B | 52.99% |
| 2014-03-31 | $10.81B | $20.41B | $9.60B | 52.97% |
| 2013-12-31 | $10.71B | $20.31B | $9.61B | 52.71% |
| 2013-09-30 | $10.60B | $20.13B | $9.54B | 52.64% |
| 2013-06-30 | $10.57B | $20.05B | $9.48B | 52.72% |
| 2013-03-31 | $10.63B | $20.12B | $9.48B | 52.86% |
| 2012-12-31 | $10.65B | $20.32B | $9.66B | 52.43% |
| 2012-09-30 | $10.75B | $20.74B | $10.00B | 51.81% |
| 2012-06-30 | $10.39B | $20.12B | $9.72B | 51.67% |
| 2012-03-31 | $9.94B | $19.33B | $9.40B | 51.39% |
| 2011-12-31 | $9.52B | $18.31B | $8.80B | 51.96% |
| 2011-09-30 | $9.10B | $17.05B | $7.96B | 53.35% |
| 2011-06-30 | $9.32B | $16.96B | $7.64B | 54.95% |
| 2011-03-31 | $9.24B | $16.55B | $7.31B | 55.84% |
| 2010-12-31 | $9.06B | $16.12B | $7.06B | 56.23% |
| 2010-09-30 | $8.70B | $15.51B | $6.80B | 56.11% |
| 2010-06-30 | $8.16B | $14.80B | $6.64B | 55.12% |
| 2010-03-31 | $7.81B | $14.40B | $6.60B | 54.21% |
| 2009-12-31 | $7.37B | $13.90B | $6.53B | 53.00% |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) |
| 2008-12-31 | $5.97B | $11.09B | $5.12B | 53.84% |
| 2008-09-30 | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) |
| 2008-03-31 | (m) | (m) | (m) | (m) |
| 2007-12-31 | $4.88B | $9.41B | $4.53B | 51.84% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.